Century Therapeutics, Inc.
IPSC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.02 | 0.44 |
| FCF Yield | -57.93% | -84.56% | -30.69% | -19.01% |
| EV / EBITDA | -1.36 | 0.54 | -2.42 | -5.26 |
| Quality | ||||
| ROIC | -12.40% | 23.86% | -16.82% | -9.24% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.74 | 0.85 | -0.45 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 257.14% | 192.43% | 169.64% | 8.22% |
| Free Cash Flow Growth | 19.39% | -42.03% | 11.45% | 0.25% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 0.01 | 0.15 | -0.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -90.20 | 0.81 | 32.78 | 153.49 |